EP4701631A1 - Dispersions de lévothyroxine - Google Patents

Dispersions de lévothyroxine

Info

Publication number
EP4701631A1
EP4701631A1 EP24796417.4A EP24796417A EP4701631A1 EP 4701631 A1 EP4701631 A1 EP 4701631A1 EP 24796417 A EP24796417 A EP 24796417A EP 4701631 A1 EP4701631 A1 EP 4701631A1
Authority
EP
European Patent Office
Prior art keywords
levothyroxine
pharmaceutically acceptable
pharmaceutical
pharmaceutical dispersion
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24796417.4A
Other languages
German (de)
English (en)
Inventor
Srikanth SUNDARAM
Riyaz Ahammad SHAIK
Lakshmikantha Reddy PONNAPUREDDY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maiaresearch India Private Ltd
Maia Pharmaceuticals Inc
Original Assignee
Maiaresearch India Private Ltd
Maia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maiaresearch India Private Ltd, Maia Pharmaceuticals Inc filed Critical Maiaresearch India Private Ltd
Publication of EP4701631A1 publication Critical patent/EP4701631A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des dispersions pharmaceutiques comprenant de la lévothyroxine ou ses sels pharmaceutiquement acceptables qui sont principalement dispersés (par exemple, principalement en suspension) dans un support pharmaceutiquement acceptable. Ces dispersions pharmaceutiques de lévothyroxine peuvent être à action prolongée et sont utiles dans le traitement et/ou la prévention du coma, de l'hypothyroïdie et/ou d'autres troubles thyroïdiens.
EP24796417.4A 2023-04-28 2024-04-27 Dispersions de lévothyroxine Pending EP4701631A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202311030765 2023-04-28
PCT/IB2024/054111 WO2024224373A1 (fr) 2023-04-28 2024-04-27 Dispersions de lévothyroxine

Publications (1)

Publication Number Publication Date
EP4701631A1 true EP4701631A1 (fr) 2026-03-04

Family

ID=93256005

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24796417.4A Pending EP4701631A1 (fr) 2023-04-28 2024-04-27 Dispersions de lévothyroxine

Country Status (2)

Country Link
EP (1) EP4701631A1 (fr)
WO (1) WO2024224373A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL292487A (en) * 2019-11-01 2022-06-01 Aquestive Therapeutics Inc Compositions of medicinal meters and methods of treatment
US20250268830A1 (en) * 2021-10-06 2025-08-28 Pharmathen S.A. Sustained release injectable pharmaceutical formulation of levothyroxine and process for preparation thereof

Also Published As

Publication number Publication date
WO2024224373A1 (fr) 2024-10-31

Similar Documents

Publication Publication Date Title
EP3442586B1 (fr) Formulation parentérale stable de nimopidine
CN107810000B (zh) 来氟米林的可注射药物组合物
US8481589B2 (en) Taxoid-based compositions
US10278946B2 (en) Liquid formulation of cabazitaxel
US20230201300A1 (en) Stable intranasal formulations of carbetocin
WO2024224373A1 (fr) Dispersions de lévothyroxine
EP4192428A1 (fr) Compositions de phytonadione
RU2861681C2 (ru) Композиция наночастиц для быстрого суспендирования и способ ее получения
WO2026062692A1 (fr) Compositions injectables prêtes à l'emploi de métolazone
WO2024112860A1 (fr) Nouvelle formulation de solution de cyclophosphamide
EP4531837A1 (fr) Compositions pharmaceutiques lyophilisées d'histidinate de cuivre
EP4025205A1 (fr) Formulations liquides de cabazitaxel
EP4676487A1 (fr) Compositions injectables de métolazone
NZ773548B2 (en) Stable intranasal formulations of carbetocin
WO2024127418A1 (fr) Compositions injectables de posaconazole
WO2023148763A1 (fr) Compositions pharmaceutiques injectables d'agents antifongiques de type azole
HK40077694A (en) Stable nimodipine parenteral formulation
US20190274986A1 (en) Sterile injectable composition comprising melphalan
US20190275102A1 (en) Sterile injectable composition comprising carfilzomib
US20170128542A1 (en) Non-aqueous glucagon formulations

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251127

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR